Table 2.
Health care–associated infections in patients without diabetes
| Outcome measures | TXA (n = 204) | Placebo (n = 200) | RR (95% CI) | P |
|---|---|---|---|---|
| Primary end point | ||||
| Health care–associated infection | 43 (21.1) | 63 (31.5) | 0.67 (0.48-0.94) | .017 |
| Secondary end points* | 23 (11.3) | 22 (11.0) | 1.03 (0.59-1.78) | .93 |
| Pneumonia | ||||
| SSI | 22 (10.8) | 36 (18.0) | 0.60 (0.37-0.98) | .039 |
| Superficial | 17 (8.3) | 32 (16.0) | 0.52 (0.30-0.91) | .018 |
| Deep | 4 (2.0) | 4 (2.0) | 0.98 (0.25-3.87) | .98 |
| Organ space | 1 (0.5) | 2 (1.0) | 0.49 (0.05-5.36) | .62† |
| Sepsis | 21 (10.3) | 31 (15.5) | 0.66 (0.40-1.12) | .12 |
| Bacteremia | 2 (1.0) | 1 (0.5) | 1.96 (0.18-21.5) | .57† |
| Catheter line infection | 2 (1.0) | 0 (0.0) | — | .50† |
All data are n (%). The dash indicates that the RR cannot be determined. Bold indicates significant results.
*
Patients could have >1 site of infection.
†
Fisher’s exact test.